GIP and Obesity: Notably, in adults with T2D at high or very high CV risk, AD1 is recommended for the reduction of CV events; if obesity is present, GLP-1 RA or GIP/GLP-1 receptor co-agonists (e.g., tirzepatide) should be considered, independently of HbA1c, for improving weight loss.